Selected article for: "clinical course and early stage"
Author: Yabing Guo; Yingxia Liu; Jiatao Lu; Rong Fan; Fuchun Zhang; Xueru Yin; Zhihong Liu; Qinglang Zeng; Jing Yuan; Shufang Hu; Qiongya Wang; Baolin Liao; Mingxing Huang; Sichun Yin; Xilin Zhang; Rui Xin; Zhanzhou Lin; Changzheng Hu; Boliang Zhao; Ridong He; Minfeng Liang; Zheng Zhang; Li Liu; Jian Sun; Lu Tang; Lisi Deng; Jinyu Xia; Xiaoping Tang; Lei Liu; Jinlin Hou
Title: Development and validation of an early warning score (EWAS) for predicting clinical deterioration in patients with coronavirus disease 2019
  • Document date: 2020_4_21
    • ID: e2wevpi6_2
    Snippet: The copyright holder for this preprint (which was not peer-reviewed) is the . https://doi.org/10.1101/2020.04. 17.20064691 doi: medRxiv preprint comparison to patients with mild pneumonia, frequently have elevated C-reactive protein (CRP), decreased lymphocytes, and elevated D-dimer. [5] [6] [7] [8] [9] [10] Preliminary data from the WHO suggest that the time interval from onset of symptoms to the development of severe disease is one week. 4 Thus.....
    Document: The copyright holder for this preprint (which was not peer-reviewed) is the . https://doi.org/10.1101/2020.04. 17.20064691 doi: medRxiv preprint comparison to patients with mild pneumonia, frequently have elevated C-reactive protein (CRP), decreased lymphocytes, and elevated D-dimer. [5] [6] [7] [8] [9] [10] Preliminary data from the WHO suggest that the time interval from onset of symptoms to the development of severe disease is one week. 4 Thus, efficient and timely management of patients with a high risk of developing severe COVID-19 is crucial in the face of severe resource constraints. Currently, there are no effective prediction tools for the early stratification of COVID-19 patients according to different risks of clinical deterioration. We therefore conducted this study with the aim to develop and validate an early warning score for predicting the clinical course of patients with COVID-19. We hypothesized that this score could be used as an efficient and widely applicable evaluation tool to prioritize managing patients with a high risk of developing severe to critical COVID-19 at an early stage.

    Search related documents:
    Co phrase search for related documents
    • clinical course and different risk: 1, 2, 3, 4, 5, 6, 7, 8, 9
    • clinical course and early stage: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • clinical course and early stratification: 1, 2, 3
    • clinical course and early warning score: 1, 2, 3
    • clinical course and evaluation tool: 1, 2, 3
    • clinical deterioration and critical severe develop: 1
    • clinical deterioration and different risk: 1
    • clinical deterioration and early stage: 1, 2, 3, 4, 5, 6, 7, 8
    • clinical deterioration and early stratification: 1, 2, 3
    • clinical deterioration and early warning score: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • critical severe develop and decrease lymphocyte: 1
    • critical severe develop and different risk: 1, 2
    • critical severe develop and early stage: 1
    • critical severe develop and early stratification: 1
    • decrease lymphocyte and early stage: 1, 2, 3, 4, 5
    • different risk and early stage: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19
    • different risk and early stratification: 1
    • different risk and early warning score: 1, 2, 3
    • different risk and evaluation tool: 1